Back to News
Market Impact: 0.25
Goldman Sachs Initiates Coverage of United Therapeutics with Sell Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Goldman Sachs initiated coverage of United Therapeutics (NASDAQGS: UTHR) with a Sell recommendation on September 24, 2026. The negative analyst initiation is a near-term headwind for the biotechnology company’s shares, though the report provides no price target, valuation rationale, or fundamental forecast changes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
UTHR-0.70
More News
- Goldman’s Moe Says He’s in ‘Stronger-for-Longer Camp’ on AI
- Why Iovance Biotherapeutics Stock Was on Fire Today
- Goldman predicts this global digital bank that just launched in the U.S. could jump nearly 70%
- Bond Yields Soar, Spiking Fed Rate Hike Bets
- New Tech Issuance Repricing Existing Debt: Rosner
- Market Indexes Fall Again as the 30-Year Yield Hits a 2004 High